Independent US Healthcare Provider Directory & Public Medical Database Patient Guides

Dr. Dario Kivelevitch , MD

Dermatology • Lancaster, TX

Active NPI 1922485838 Individual Practitioner Male Practitioner Accepts Medicare assignment
Practice location in NPPES

2500 W Pleasant Run Rd Ste 215
Lancaster, TX 751461170

Call 9452304312 Location details and other listings
Medical Disclaimer

This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.

Practice Location & Contact Primary Location

Practice Address

2500 W Pleasant Run Rd Ste 215

Lancaster, TX 751461170

Telephone 9452304312
Organization at the Same NPPES Address or Phone
Clarity Dermatology Pllc Facility NPI 1093447252

Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.

Other Listings in Public Data

NPPES lists 2 distinct additional practice-address records in Dallas, TX. See the list

Source: CMS NPPES NPI Registry, practice location records; release date unavailable.

CMS Doctors and Clinicians lists 1 group name: Oliver Street 5.01(A) Inc. See the list

Source: CMS Doctors and Clinicians National Downloadable File, release date unavailable.

Listings do not confirm current availability, employment or a shared ownership network.

Medicare Profile & Education

Source: CMS Doctors and Clinicians National Downloadable File

Graduation Year

2000

Medicare patients

262 people with Original Medicare in 2024

Different Original Medicare patients in 2024; counts below 11 are hidden; this does not show availability or quality.

Source: CMS, Medicare Physician & Other Practitioners – by Provider, 2024.

Medicare-allowed amount

About $94,250 in 2024

The total amount Medicare approved for these services in 2024. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.

What this does not show: Medicare-allowed amount

This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.

Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.

Paid by Medicare

About $69,572 in 2024

The part of the Medicare-allowed amount that Medicare itself paid in 2024, after patients' deductibles and coinsurance.

What this does not show: Paid by Medicare

This is not the clinician's income and not a measure of quality.

Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.

30-day fills

743 standardized 30-day fills in 2024

CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.

What this does not show: 30-day fills

It is not a count of patients and not a measure of quality.

Part D drug cost

$256,290 in 2024

The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.

What this does not show: Part D drug cost

A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.

Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024.

Open Payments general payments, program year 2025

All general payments: $44,043.85 across 253 records.

By nature of payment (3 largest of 5)

  • Consulting Fee: $20,036.00 across 3 records.
  • Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program: $14,965.00 across 2 records.
  • Travel and Lodging: $4,574.84 across 20 records.

Reporting-company totals (3 largest of 21)

  • Boehringer Ingelheim Pharmaceuticals, Inc.: $16,672.39 across 12 records.
  • Janssen Pharmaceuticals, Inc: $9,143.34 across 34 records.
  • Takeda Pharmaceuticals U.S.A., Inc.: $8,023.17 across 13 records.

A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.

See the full table

Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).

Guide: How to read an Open Payments record

Years since graduation

26 years (graduated 2000)

CMS Doctors and Clinicians data list 2000 as the year this clinician finished professional school.

What this does not show: Years since graduation

It is not the number of years in practice, and more years does not mean better care.

Source: CMS Doctors and Clinicians National Downloadable File.

NPI first issued

2015

The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.

What this does not show: NPI first issued

NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.

Source: CMS NPPES NPI Registry.

Accepts Medicare assignment

CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.

Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.

Source: CMS Doctors and Clinicians; Medicare.gov, “Does your provider accept Medicare as full payment?”

Guide: What Medicare assignment means

No telehealth indicator

CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.

Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians.

Guide: How Medicare covers telehealth

Enrolled in Medicare (PECOS)

Dr. Kivelevitch has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.

It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.

Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.

Guide: What Medicare enrollment (PECOS) means

Can order Medicare-covered services

CMS lists Dr. Kivelevitch as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.

What this does not show: Can order Medicare-covered services

It does not mean the clinician offers these services directly.

Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.

Guide: What ordering and referring status means

Compared with the same specialty in Lancaster and Texas

Billing and prescribing volume is not a quality rating.

Medicare Part B services

Fewer Medicare Part B services than 70% of clinicians listed under Dermatology in Texas (2024, 827 clinicians with data). Median for this group: 2,195. Middle half: 1,085 to 4,742.

Too few clinicians listed under Dermatology in Lancaster have Medicare Part B data for 2024 to compare.

Medicare-allowed amount

A lower Medicare-allowed amount than 60% of clinicians listed under Dermatology in Texas (2024, 827 clinicians with data). Median for this group: $135,212. Middle half: $65,517 to $291,099.

Too few clinicians listed under Dermatology in Lancaster have Medicare Part B data for 2024 to compare.

Paid by Medicare

A lower Medicare payment amount than 60% of clinicians listed under Dermatology in Texas (2024, 827 clinicians with data). Median for this group: $95,715. Middle half: $45,692 to $209,369.

Too few clinicians listed under Dermatology in Lancaster have Medicare Part B data for 2024 to compare.

Medicare Part D prescriptions

Close to the middle for clinicians listed under Dermatology in Texas (2024, 922 clinicians with data). Median for this group: 486. Middle half: 202 to 949.

Too few clinicians listed under Dermatology in Lancaster have Medicare Part D data for 2024 to compare.

Part D drug cost

A higher Part D drug cost than 75% of clinicians listed under Dermatology in Texas (2024, 922 clinicians with data). Median for this group: $81,547. Middle half: $6,986 to $226,319.

Too few clinicians listed under Dermatology in Lancaster have Medicare Part D data for 2024 to compare.

1 active clinicians are listed under Dermatology with a practice address in Lancaster, TX (1,173 in Texas).

Addresses are self-reported to NPPES and may be out of date.

Sources: CMS Medicare Physician & Other Practitioners (2024), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.

Text: T-MedInfo · Report an error.

Pharma & Medical Device Financial Disclosures

Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments

Open Payments · Program Year 2025
Disclosure Year:

Program year 2025 (payments made January 1 – December 31, 2025): 253 records totaling $44,043.85.

Manufacturer Payment Nature Product Type Amount ($)
Boehringer Ingelheim Pharmaceuticals, Inc.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
SPEVIGO General $7,950.00
Janssen Pharmaceuticals, Inc
Consulting Fee
Cash or cash equivalent
TREMFYA General $7,650.00
Boehringer Ingelheim Pharmaceuticals, Inc.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
SPEVIGO General $7,015.00
Takeda Pharmaceuticals U.S.A., Inc.
Consulting Fee
Cash or cash equivalent
— General $6,636.00
Novartis Pharmaceuticals Corporation
Consulting Fee
Cash or cash equivalent
COSENTYX General $5,750.00
Boehringer Ingelheim Pharmaceuticals, Inc.
Travel and Lodging
In-kind items and services
SPEVIGO General $752.12
Takeda Pharmaceuticals U.S.A., Inc.
Travel and Lodging
In-kind items and services
— General $630.57
Janssen Pharmaceuticals, Inc
Travel and Lodging
In-kind items and services
TREMFYA General $596.17
Novartis Pharmaceuticals Corporation
Travel and Lodging
In-kind items and services
COSENTYX General $513.45
Novartis Pharmaceuticals Corporation
Travel and Lodging
Cash or cash equivalent
COSENTYX General $275.13
Takeda Pharmaceuticals U.S.A., Inc.
Travel and Lodging
In-kind items and services
— General $268.85
Janssen Pharmaceuticals, Inc
Travel and Lodging
In-kind items and services
TREMFYA General $243.21
Novartis Pharmaceuticals Corporation
Travel and Lodging
In-kind items and services
COSENTYX General $236.16
Boehringer Ingelheim Pharmaceuticals, Inc.
Travel and Lodging
In-kind items and services
SPEVIGO General $182.17
Galderma Laboratories, L.P.
Food and Beverage
In-kind items and services
NEMLUVIO General $160.83
Takeda Pharmaceuticals U.S.A., Inc.
Travel and Lodging
In-kind items and services
— General $158.16
Boehringer Ingelheim Pharmaceuticals, Inc.
Travel and Lodging
In-kind items and services
SPEVIGO General $137.66
Boehringer Ingelheim Pharmaceuticals, Inc.
Travel and Lodging
In-kind items and services
SPEVIGO General $132.71
Boehringer Ingelheim Pharmaceuticals, Inc.
Travel and Lodging
In-kind items and services
SPEVIGO General $130.67
Boehringer Ingelheim Pharmaceuticals, Inc.
Food and Beverage
In-kind items and services
SPEVIGO General $123.50
Novartis Pharmaceuticals Corporation
Food and Beverage
In-kind items and services
COSENTYX General $122.07
Boehringer Ingelheim Pharmaceuticals, Inc.
Food and Beverage
In-kind items and services
SPEVIGO General $107.10
Boehringer Ingelheim Pharmaceuticals, Inc.
Travel and Lodging
In-kind items and services
SPEVIGO General $106.14
Takeda Pharmaceuticals U.S.A., Inc.
Food and Beverage
In-kind items and services
— General $75.00
Janssen Pharmaceuticals, Inc
Food and Beverage
In-kind items and services
TREMFYA General $57.00

(top 25 shown)

Source: CMS Open Payments, program year 2025, released June 30, 2026.

Performed Procedures & Service Volume

Services billed to Original Medicare Part B in 2024.

CMS Part B · Data Year 2024
Reporting Year:

CPT® is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2017–2023 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners – by Provider and Service data, 2018–2024; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS Code Services Patients Submitted Charge Medicare Allowed
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
243 146 $368.20 $126.26
17003 Destruction of precancer skin growth, 2-14 growths
230 55 $19.57 $6.59
17110 Destruction of skin growth, 1-14 growths
168 121 $320.67 $109.94
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
132 102 $258.81 $89.57
17000 Destruction of precancer skin growth, 1 growth
114 82 $187.71 $44.98
11102 Biopsy of related skin growth, first growth
97 76 $286.29 $74.13
11103 Biopsy of related skin growth, each additional growth
41 31 $138.31 $48.29
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
31 31 $409.42 $161.04
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
24 21 $159.27 $55.76
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
22 22 $279.46 $110.02
11602 Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm
19 15 $598.36 $158.91
12032 Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm
19 14 $741.79 $299.54

Source: CMS Part B by Provider and Service, 2024; services under 11 beneficiaries omitted by CMS. Privacy limits

Submitted charges are billed amounts, not a price quote for your visit.

Medicare Part D Prescribing Profile & Medications

Medicare Part D prescriptions filled, including refills, in 2024.

CMS Part D · Data Year 2024
Prescription Year:
Brand Name Generic Name Prescriptions Day Supply Total Cost Patients
Clobetasol Propionate Clobetasol Propionate 100 2,996 $5,664.71 47
Ketoconazole Ketoconazole 74 2,143 $1,105.62 30
Triamcinolone Acetonide Triamcinolone Acetonide 68 1,741 $793.95 47
Minoxidil Minoxidil 46 3,990 $548.29 18
Dutasteride Dutasteride 36 3,180 $1,109.21 12
Hydrocortisone Hydrocortisone 33 769 $278.98 23
Doxycycline Hyclate Doxycycline Hyclate 30 467 $351.58 25
Doxycycline Monohydrate Doxycycline Monohydrate 29 432 $589.04 23
Clotrimazole Clotrimazole 22 534 $391.41 15
Methotrexate Methotrexate Sodium 17 602 $337.67 —
Terbinafine Hcl Terbinafine Hcl 14 540 $165.73 12
Tretinoin Tretinoin 14 462 $863.19 —
Acitretin Acitretin 14 480 $3,230.21 —
Humira Pen Adalimumab 14 392 $95,361.84 —
Dupixent Pen Dupilumab 14 406 $63,189.17 —
Valacyclovir Valacyclovir Hcl 13 560 $573.50 —
Humira(Cf) Pen Adalimumab 12 336 $81,735.42 —

Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits

Specialties & License Numbers Reported to NPPES

Self-certified to NPPES: 2023-06-20
Dermatology Primary Specialty

NUCC Taxonomy Code: 207N00000X

License # reported to NPPES TX R6810

A dermatologist is trained to diagnose and treat pediatric and adult patients with benign and malignant disorders of the skin, mouth, external genitalia, hair and nails, as well as a number of sexually transmitted diseases. The dermatologist has had additional training and experience in the diagnosis and treatment of skin cancers, melanomas, moles and other tumors of the skin, the management of contact dermatitis and other allergic and nonallergic skin disorders, and in the recognition of the skin manifestations of systemic (including internal malignancy) and infectious diseases. Dermatologists have special training in dermatopathology and in the surgical techniques used in dermatology. They also have expertise in the management of cosmetic disorders of the skin such as hair loss and scars and the skin changes associated with aging.

Check License Status with the State Board License numbers are self-reported to NPPES; T-MedInfo does not confirm them against state records. Current status: Texas Medical Board.
Look Up on State Board Site

Medicare (PECOS) Enrollment & Ordering Eligibility

Source: CMS PECOS
Medicare FFS Enrollment Status Medicare Enrollment on File
CMS Provider Specialty

PRACTITIONER - DERMATOLOGY

Medicare Enrollment ID

I20180815001571

Enrollment State Jurisdiction

TX

PECOS Control ID

6800116807

Medicare Order & Referring Eligibility
Clinical Lab & Imaging (Part B) Eligible
Durable Medical Equipment (DME) Eligible
Home Health Agency (HHA) Eligible
Power Mobility Devices (PMD) Eligible

Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.

Medicare Group Practice Enrollments

Source: CMS Doctors and Clinicians National Downloadable File

Oliver Street 5.01(A) Inc

8220 Walnut Hill Ln, Dallas, TX 752314414

Phone: 2143698130

Secondary Practice Locations

3500 Gaston Ave

Dallas, TX 752462017

Phone: 2148202361

8210 Walnut Hill Ln Ste 810

Dallas, TX 752314421

Phone: 2149030829

Clinicians Sharing This Practice Address or Phone

Clinicians sharing this NPPES address, phone or fax; a shared contact does not mean they work together.

1 listed
Oladimeji Sorunke , PA

Physician Assistant

NPI 1538182936

Physician Assistant

Career & Practice History Timeline

Changes recorded in monthly NPPES data files: addresses, names, credentials, specialties and NPI status

10 Historical Events
📍
Updated Business Mailing Address June 20, 2023

Registered at 2500 W PLEASANT RUN RD STE 215, LANCASTER, TX 751461170 (Tel: 9452304312)

📍
Updated Practice Location October 03, 2022

Registered at 2500 W PLEASANT RUN RD STE 215, LANCASTER, TX 751461170 (Tel: 9452304312)

📍
Updated Business Mailing Address October 03, 2022

Registered at 7150 E GRAND AVE APT 1112, DALLAS, TX 752233663 (Tel: 4692867909)

🎓
Medical Taxonomy / Specialty Registered (Primary Specialty) November 12, 2020

Dermatology (license number reported to NPPES: TX R6810)

âś…
NPI Profile Active April 29, 2015

NPI status registered as active in NPPES database

📍
Practice Location (Initial Record) April 29, 2015

Registered at 3500 GASTON AVE, DALLAS, TX 752462017 (Tel: 2148202361)

📍
Business Mailing Address (Initial Record) April 29, 2015

Registered at 7510 E. GRAND AVE, APT. 4304, DALLAS, TX 752146121 (Tel: 4692867909)

👤
Provider Name / Credentials (Initial Record) April 29, 2015

Recorded as DARIO KIVELEVITCH, M.D.

🎓
Medical Taxonomy / Specialty Registered (Primary Specialty) April 29, 2015

Student in an Organized Health Care Education/Training Program

🟢
Initial NPI Registration & Enumeration April 29, 2015

First registered as active Individual Practitioner in NPPES Database.

No reviews have been published yet. Leave a review.

NPI Administrative Meta

NPI Number: 1922485838
Entity Type:
Individual Provider Physician, Nurse Practitioner, or Solo Healthcare Professional (Type 1 NPI)
Enumeration Date: April 29, 2015
Last Update: June 20, 2023
Sole Proprietor: No

Mailing Address

2500 W Pleasant Run Rd Ste 215

Lancaster, TX 751461170

Phone: 9452304312

About This Data NPPES fields (address, phone, specialty, license) are self-reported and may be outdated; Medicare fields follow the CMS dataset named in each section. Correct directly at NPPES.